AGE/RAGE produces endothelial dysfunction in coronary arterioles in type 2 diabetic mice.

We hypothesized that impaired nitric oxide (NO)-dependent dilation (endothelial dysfunction) in type 2 diabetes results, in part, from elevated production of superoxide (O(2)(*-)) induced by the interaction of advanced glycation end products (AGE)/receptor for AGE (RAGE) and TNF-alpha signaling. We assessed the role of AGE/RAGE and TNF-alpha signaling in endothelial dysfunction in type 2 diabetic (Lepr(db)) mice by evaluation of endothelial function in isolated coronary resistance vessels of normal control (nondiabetic, m Lepr(db)) and diabetic mice. Although dilation of vessels to the endothelium-independent vasodilator sodium nitroprusside (SNP) was not different between diabetic and control mice, dilation to the endothelium-dependent agonist acetylcholine (ACh) was reduced in diabetic vs. control mice. The activation of RAGE with RAGE agonist S100b eliminated SNP-potentiated dilation to ACh in Lepr(db) mice. Administration of a soluble form of RAGE (sRAGE) partially restored dilation in diabetic mice but did not affect dilation in control mice. The expression of RAGE in coronary arterioles was markedly increased in diabetic vs. control mice. We also observed in diabetic mice that augmented RAGE signaling augmented expression of TNF-alpha, because this increase was attenuated by sRAGE or NF-kappaB inhibitor MG132. Protein and mRNA expression of NAD(P)H oxidase subunits including NOX-2, p22(phox), and p40(phox) increased in diabetic compared with control mice. sRAGE significantly inhibited the expression of NAD(P)H oxidase in diabetic mice. These results indicate that AGE/RAGE signaling plays a pivotal role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes.

[1]  N. Tewari-Singh,et al.  Tumor Necrosis Factor-α Induces Endothelial Dysfunction in Leprdb Mice , 2007 .

[2]  S. Yagihashi,et al.  Effect of Aminoguanidine on Functional and Structural Abnormalities in Peripheral Nerve of STZ-Induced Diabetic Rats , 1992, Diabetes.

[3]  L. Velloso,et al.  Increased expression of advanced glycation end-products and their receptor, and activation of nuclear factor kappa-B in lacrimal glands of diabetic rats , 2005, Diabetologia.

[4]  M. Andrassy,et al.  Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. , 2001, Diabetes.

[5]  M. Focardi,et al.  Tumor Necrosis Factor- (cid:1) Induces Endothelial Dysfunction in the Prediabetic Metabolic Syndrome , 2022 .

[6]  Alan W. Stitt,et al.  Advanced glycation end products (AGEs) co-localize with AGE receptors in the retinal vasculature of diabetic and of AGE-infused rats. , 1997, The American journal of pathology.

[7]  Lei Feng,et al.  Chronic vascular inflammation in patients with type 2 diabetes: endothelial biopsy and RT-PCR analysis. , 2005, Diabetes care.

[8]  P. Low,et al.  Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Hiroshi Yamamoto,et al.  The Receptor for Advanced Glycation End Products Is Induced by the Glycation Products Themselves and Tumor Necrosis Factor-α through Nuclear Factor-κB, and by 17β-Estradiol through Sp-1 in Human Vascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[10]  L. Kuo,et al.  Myogenic activity in isolated subepicardial and subendocardial coronary arterioles. , 1988, The American journal of physiology.

[11]  A. Schmidt,et al.  Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts , 1998, Nature Medicine.

[12]  Merlin C. Thomas,et al.  Advanced glycation end product interventions reduce diabetes-accelerated atherosclerosis. , 2004, Diabetes.

[13]  A. M. Lefer,et al.  Cytokines and growth factors in endothelial dysfunction , 1993, Critical care medicine.

[14]  L. Kuo,et al.  TNF-alpha contributes to endothelial dysfunction in ischemia/reperfusion injury. , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[15]  Y. Zou,et al.  Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. , 1994, The Journal of biological chemistry.

[16]  I. Boros,et al.  The proteasome inhibitor MG132 protects against acute pancreatitis. , 2005, Free radical biology & medicine.

[17]  A. Schmidt,et al.  RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes. , 2006, Atherosclerosis.

[18]  R. Furchgott,et al.  The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine , 1980, Nature.

[19]  S. Spiegel,et al.  Sphingosine kinase functionally links elevated transmural pressure and increased reactive oxygen species formation in resistance arteries , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[20]  L. Køber,et al.  Tumor Necrosis Factor-&agr; Inhibits Insulin’s Stimulating Effect on Glucose Uptake and Endothelium-Dependent Vasodilation in Humans , 2003, Circulation.

[21]  A. Schmidt,et al.  Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. , 2001, American journal of physiology. Endocrinology and metabolism.

[22]  E. Diamanti-Kandarakis,et al.  Increased levels of serum advanced glycation end‐products in women with polycystic ovary syndrome , 2005, Clinical endocrinology.

[23]  T. Hughes,et al.  Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA. , 2004, Diabetes.

[24]  R. Bucala,et al.  Advanced glycation end products and endothelial dysfunction in type 2 diabetes. , 2002, Diabetes care.

[25]  H. Yamamoto,et al.  The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa B, and by 17beta-estradiol through Sp-1 in human vascular endothelial cells. , 2000, The Journal of biological chemistry.

[26]  堀江 勝智.  Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions : implication for glycoxidative stress in the pathogenesis of diabetic nephropathy , 1998 .

[27]  L. Kuo,et al.  TNF-&agr; Contributes to Endothelial Dysfunction in Ischemia/Reperfusion Injury , 2005 .

[28]  Peter Libby,et al.  Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. , 2002, JAMA.

[29]  K. Tracey,et al.  Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. , 1991, The Journal of clinical investigation.

[30]  Thomas D. Schmittgen,et al.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. , 2001, Methods.

[31]  R. Hofer-Warbinek,et al.  The Transcription Factor NF-κB and the Regulation of Vascular Cell Function , 2000 .